Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
